Nakamoto Inc.
Nakamoto Inc. (NAKAW) Stock Competitors & Peer Comparison
See (NAKAW) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NAKAW | $15.30 | +7.75% | 116.4M | N/A | N/A | N/A |
| HCA | $528.66 | +0.00% | 119.1B | 18.79 | $28.34 | +0.54% |
| THC | $228.08 | +0.00% | 20.2B | 15.64 | $14.71 | N/A |
| UHS | $230.00 | +0.00% | 14.9B | 10.96 | $21.02 | +0.35% |
| FMS | $24.11 | +0.00% | 14.2B | 16.82 | $1.45 | +3.23% |
| SOLV | $73.61 | +0.00% | 12.6B | 8.37 | $8.71 | N/A |
| ENSG | $204.78 | +0.00% | 12.2B | 36.07 | $5.84 | +0.12% |
| EHC | $107.15 | +0.00% | 10.7B | 19.20 | $5.55 | +0.68% |
| DVA | $147.34 | +0.00% | 10.1B | 15.84 | $9.52 | N/A |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
Stock Comparison
NAKAW vs HCA Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, HCA has a market cap of 119.1B. Regarding current trading prices, NAKAW is priced at $15.30, while HCA trades at $528.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas HCA's P/E ratio is 18.79. In terms of profitability, NAKAW's ROE is -0.74%, compared to HCA's ROE of -1.41%. Regarding short-term risk, NAKAW is more volatile compared to HCA. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check HCA's competition here
NAKAW vs THC Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, THC has a market cap of 20.2B. Regarding current trading prices, NAKAW is priced at $15.30, while THC trades at $228.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas THC's P/E ratio is 15.64. In terms of profitability, NAKAW's ROE is -0.74%, compared to THC's ROE of +0.35%. Regarding short-term risk, NAKAW is more volatile compared to THC. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check THC's competition here
NAKAW vs UHS Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, UHS has a market cap of 14.9B. Regarding current trading prices, NAKAW is priced at $15.30, while UHS trades at $230.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas UHS's P/E ratio is 10.96. In terms of profitability, NAKAW's ROE is -0.74%, compared to UHS's ROE of +0.20%. Regarding short-term risk, NAKAW is more volatile compared to UHS. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check UHS's competition here
NAKAW vs FMS Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, FMS has a market cap of 14.2B. Regarding current trading prices, NAKAW is priced at $15.30, while FMS trades at $24.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas FMS's P/E ratio is 16.82. In terms of profitability, NAKAW's ROE is -0.74%, compared to FMS's ROE of +0.05%. Regarding short-term risk, NAKAW is more volatile compared to FMS. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check FMS's competition here
NAKAW vs SOLV Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, SOLV has a market cap of 12.6B. Regarding current trading prices, NAKAW is priced at $15.30, while SOLV trades at $73.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas SOLV's P/E ratio is 8.37. In terms of profitability, NAKAW's ROE is -0.74%, compared to SOLV's ROE of +0.41%. Regarding short-term risk, NAKAW is more volatile compared to SOLV. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check SOLV's competition here
NAKAW vs ENSG Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, ENSG has a market cap of 12.2B. Regarding current trading prices, NAKAW is priced at $15.30, while ENSG trades at $204.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas ENSG's P/E ratio is 36.07. In terms of profitability, NAKAW's ROE is -0.74%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, NAKAW is more volatile compared to ENSG. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check ENSG's competition here
NAKAW vs EHC Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, EHC has a market cap of 10.7B. Regarding current trading prices, NAKAW is priced at $15.30, while EHC trades at $107.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas EHC's P/E ratio is 19.20. In terms of profitability, NAKAW's ROE is -0.74%, compared to EHC's ROE of +0.23%. Regarding short-term risk, NAKAW is more volatile compared to EHC. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check EHC's competition here
NAKAW vs DVA Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, DVA has a market cap of 10.1B. Regarding current trading prices, NAKAW is priced at $15.30, while DVA trades at $147.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas DVA's P/E ratio is 15.84. In terms of profitability, NAKAW's ROE is -0.74%, compared to DVA's ROE of -1.61%. Regarding short-term risk, NAKAW is more volatile compared to DVA. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check DVA's competition here
NAKAW vs OSH Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, NAKAW is priced at $15.30, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas OSH's P/E ratio is -17.65. In terms of profitability, NAKAW's ROE is -0.74%, compared to OSH's ROE of +4.64%. Regarding short-term risk, NAKAW is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check OSH's competition here
NAKAW vs CHE Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, CHE has a market cap of 6.9B. Regarding current trading prices, NAKAW is priced at $15.30, while CHE trades at $472.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas CHE's P/E ratio is 25.20. In terms of profitability, NAKAW's ROE is -0.74%, compared to CHE's ROE of +0.24%. Regarding short-term risk, NAKAW is more volatile compared to CHE. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check CHE's competition here
NAKAW vs OPCH Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, OPCH has a market cap of 5.8B. Regarding current trading prices, NAKAW is priced at $15.30, while OPCH trades at $35.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas OPCH's P/E ratio is 28.33. In terms of profitability, NAKAW's ROE is -0.74%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, NAKAW is more volatile compared to OPCH. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check OPCH's competition here
NAKAW vs LHCG Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, NAKAW is priced at $15.30, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas LHCG's P/E ratio is 82.83. In terms of profitability, NAKAW's ROE is -0.74%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, NAKAW is more volatile compared to LHCG. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check LHCG's competition here
NAKAW vs BKD Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, BKD has a market cap of 3.5B. Regarding current trading prices, NAKAW is priced at $15.30, while BKD trades at $14.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas BKD's P/E ratio is -11.29. In terms of profitability, NAKAW's ROE is -0.74%, compared to BKD's ROE of -5.24%. Regarding short-term risk, NAKAW is more volatile compared to BKD. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check BKD's competition here
NAKAW vs AMED Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, NAKAW is priced at $15.30, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas AMED's P/E ratio is 39.30. In terms of profitability, NAKAW's ROE is -0.74%, compared to AMED's ROE of +0.13%. Regarding short-term risk, NAKAW is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check AMED's competition here
NAKAW vs LFST Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, LFST has a market cap of 2.8B. Regarding current trading prices, NAKAW is priced at $15.30, while LFST trades at $7.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas LFST's P/E ratio is -238.33. In terms of profitability, NAKAW's ROE is -0.74%, compared to LFST's ROE of -0.01%. Regarding short-term risk, NAKAW is more volatile compared to LFST. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check LFST's competition here
NAKAW vs NHC Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, NHC has a market cap of 2.5B. Regarding current trading prices, NAKAW is priced at $15.30, while NHC trades at $158.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas NHC's P/E ratio is 24.42. In terms of profitability, NAKAW's ROE is -0.74%, compared to NHC's ROE of +0.10%. Regarding short-term risk, NAKAW is more volatile compared to NHC. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check NHC's competition here
NAKAW vs ADUS Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, ADUS has a market cap of 2.1B. Regarding current trading prices, NAKAW is priced at $15.30, while ADUS trades at $114.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas ADUS's P/E ratio is 24.52. In terms of profitability, NAKAW's ROE is -0.74%, compared to ADUS's ROE of +0.08%. Regarding short-term risk, NAKAW is more volatile compared to ADUS. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check ADUS's competition here
NAKAW vs SGRY Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, SGRY has a market cap of 2B. Regarding current trading prices, NAKAW is priced at $15.30, while SGRY trades at $15.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas SGRY's P/E ratio is -11.43. In terms of profitability, NAKAW's ROE is -0.74%, compared to SGRY's ROE of -0.10%. Regarding short-term risk, NAKAW is more volatile compared to SGRY. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check SGRY's competition here
NAKAW vs SEM Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, SEM has a market cap of 1.9B. Regarding current trading prices, NAKAW is priced at $15.30, while SEM trades at $16.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas SEM's P/E ratio is 18.32. In terms of profitability, NAKAW's ROE is -0.74%, compared to SEM's ROE of +0.08%. Regarding short-term risk, NAKAW is more volatile compared to SEM. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check SEM's competition here
NAKAW vs AMEH Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, NAKAW is priced at $15.30, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas AMEH's P/E ratio is 39.25. In terms of profitability, NAKAW's ROE is -0.74%, compared to AMEH's ROE of +0.02%. Regarding short-term risk, NAKAW is more volatile compared to AMEH. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check AMEH's competition here
NAKAW vs MD Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, MD has a market cap of 1.6B. Regarding current trading prices, NAKAW is priced at $15.30, while MD trades at $19.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas MD's P/E ratio is 9.87. In terms of profitability, NAKAW's ROE is -0.74%, compared to MD's ROE of +0.20%. Regarding short-term risk, NAKAW is more volatile compared to MD. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check MD's competition here
NAKAW vs AVAH Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, AVAH has a market cap of 1.5B. Regarding current trading prices, NAKAW is priced at $15.30, while AVAH trades at $7.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas AVAH's P/E ratio is 19.84. In terms of profitability, NAKAW's ROE is -0.74%, compared to AVAH's ROE of -1.36%. Regarding short-term risk, NAKAW is more volatile compared to AVAH. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check AVAH's competition here
NAKAW vs ACHC Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, ACHC has a market cap of 1.5B. Regarding current trading prices, NAKAW is priced at $15.30, while ACHC trades at $16.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas ACHC's P/E ratio is 14.47. In terms of profitability, NAKAW's ROE is -0.74%, compared to ACHC's ROE of +0.03%. Regarding short-term risk, NAKAW is more volatile compared to ACHC. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check ACHC's competition here
NAKAW vs HCSG Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, HCSG has a market cap of 1.5B. Regarding current trading prices, NAKAW is priced at $15.30, while HCSG trades at $20.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas HCSG's P/E ratio is 25.48. In terms of profitability, NAKAW's ROE is -0.74%, compared to HCSG's ROE of +0.12%. Regarding short-term risk, NAKAW is more volatile compared to HCSG. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check HCSG's competition here
NAKAW vs ARDT Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, ARDT has a market cap of 1.3B. Regarding current trading prices, NAKAW is priced at $15.30, while ARDT trades at $9.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas ARDT's P/E ratio is 6.36. In terms of profitability, NAKAW's ROE is -0.74%, compared to ARDT's ROE of +0.17%. Regarding short-term risk, NAKAW is more volatile compared to ARDT. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check ARDT's competition here
NAKAW vs USPH Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, USPH has a market cap of 1.3B. Regarding current trading prices, NAKAW is priced at $15.30, while USPH trades at $86.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas USPH's P/E ratio is 35.86. In terms of profitability, NAKAW's ROE is -0.74%, compared to USPH's ROE of +0.07%. Regarding short-term risk, NAKAW is more volatile compared to USPH. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check USPH's competition here
NAKAW vs BKDT Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, NAKAW is priced at $15.30, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas BKDT's P/E ratio is N/A. In terms of profitability, NAKAW's ROE is -0.74%, compared to BKDT's ROE of -5.24%. Regarding short-term risk, NAKAW is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check BKDT's competition here
NAKAW vs PNTG Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, PNTG has a market cap of 1.1B. Regarding current trading prices, NAKAW is priced at $15.30, while PNTG trades at $32.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas PNTG's P/E ratio is 43.09. In terms of profitability, NAKAW's ROE is -0.74%, compared to PNTG's ROE of +0.09%. Regarding short-term risk, NAKAW is more volatile compared to PNTG. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check PNTG's competition here
NAKAW vs INNV Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, INNV has a market cap of 1.1B. Regarding current trading prices, NAKAW is priced at $15.30, while INNV trades at $8.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas INNV's P/E ratio is 163.20. In terms of profitability, NAKAW's ROE is -0.74%, compared to INNV's ROE of -0.02%. Regarding short-term risk, NAKAW is more volatile compared to INNV. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check INNV's competition here
NAKAW vs ASTH Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, ASTH has a market cap of 996.1M. Regarding current trading prices, NAKAW is priced at $15.30, while ASTH trades at $19.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas ASTH's P/E ratio is 104.53. In terms of profitability, NAKAW's ROE is -0.74%, compared to ASTH's ROE of +0.01%. Regarding short-term risk, NAKAW is more volatile compared to ASTH. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check ASTH's competition here
NAKAW vs TALK Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, TALK has a market cap of 835.7M. Regarding current trading prices, NAKAW is priced at $15.30, while TALK trades at $4.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas TALK's P/E ratio is 166.33. In terms of profitability, NAKAW's ROE is -0.74%, compared to TALK's ROE of -0.05%. Regarding short-term risk, NAKAW is more volatile compared to TALK. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check TALK's competition here
NAKAW vs FSHCX Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, FSHCX has a market cap of 804.5M. Regarding current trading prices, NAKAW is priced at $15.30, while FSHCX trades at $100.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas FSHCX's P/E ratio is N/A. In terms of profitability, NAKAW's ROE is -0.74%, compared to FSHCX's ROE of N/A. Regarding short-term risk, NAKAW is more volatile compared to FSHCX. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check FSHCX's competition here
NAKAW vs CMPS Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, CMPS has a market cap of 772.8M. Regarding current trading prices, NAKAW is priced at $15.30, while CMPS trades at $8.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas CMPS's P/E ratio is -2.96. In terms of profitability, NAKAW's ROE is -0.74%, compared to CMPS's ROE of -1.72%. Regarding short-term risk, NAKAW is more volatile compared to CMPS. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check CMPS's competition here
NAKAW vs AMN Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, AMN has a market cap of 741.4M. Regarding current trading prices, NAKAW is priced at $15.30, while AMN trades at $17.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas AMN's P/E ratio is -2.68. In terms of profitability, NAKAW's ROE is -0.74%, compared to AMN's ROE of -0.15%. Regarding short-term risk, NAKAW is more volatile compared to AMN. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check AMN's competition here
NAKAW vs SNDA Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, SNDA has a market cap of 649.8M. Regarding current trading prices, NAKAW is priced at $15.30, while SNDA trades at $34.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas SNDA's P/E ratio is -11.58. In terms of profitability, NAKAW's ROE is -0.74%, compared to SNDA's ROE of -0.44%. Regarding short-term risk, NAKAW is more volatile compared to SNDA. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check SNDA's competition here
NAKAW vs EHAB Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, EHAB has a market cap of 561.1M. Regarding current trading prices, NAKAW is priced at $15.30, while EHAB trades at $11.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas EHAB's P/E ratio is -46.12. In terms of profitability, NAKAW's ROE is -0.74%, compared to EHAB's ROE of -0.02%. Regarding short-term risk, NAKAW is more volatile compared to EHAB. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check EHAB's competition here
NAKAW vs CYH Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, CYH has a market cap of 493.1M. Regarding current trading prices, NAKAW is priced at $15.30, while CYH trades at $3.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas CYH's P/E ratio is 1.45. In terms of profitability, NAKAW's ROE is -0.74%, compared to CYH's ROE of -0.35%. Regarding short-term risk, NAKAW is more volatile compared to CYH. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check CYH's competition here
NAKAW vs MCTA Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, NAKAW is priced at $15.30, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas MCTA's P/E ratio is 419.36. In terms of profitability, NAKAW's ROE is -0.74%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, NAKAW is more volatile compared to MCTA. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check MCTA's competition here
NAKAW vs AUNA Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, AUNA has a market cap of 392.1M. Regarding current trading prices, NAKAW is priced at $15.30, while AUNA trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas AUNA's P/E ratio is 5.40. In terms of profitability, NAKAW's ROE is -0.74%, compared to AUNA's ROE of +0.12%. Regarding short-term risk, NAKAW is more volatile compared to AUNA. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check AUNA's competition here
NAKAW vs AONC Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, AONC has a market cap of 351M. Regarding current trading prices, NAKAW is priced at $15.30, while AONC trades at $11.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas AONC's P/E ratio is -13.48. In terms of profitability, NAKAW's ROE is -0.74%, compared to AONC's ROE of -0.02%. Regarding short-term risk, NAKAW is more volatile compared to AONC. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check AONC's competition here
NAKAW vs CCRN Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, CCRN has a market cap of 282.1M. Regarding current trading prices, NAKAW is priced at $15.30, while CCRN trades at $8.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas CCRN's P/E ratio is -17.57. In terms of profitability, NAKAW's ROE is -0.74%, compared to CCRN's ROE of -0.04%. Regarding short-term risk, NAKAW is more volatile compared to CCRN. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check CCRN's competition here
NAKAW vs TOI Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, TOI has a market cap of 251.9M. Regarding current trading prices, NAKAW is priced at $15.30, while TOI trades at $2.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas TOI's P/E ratio is -4.00. In terms of profitability, NAKAW's ROE is -0.74%, compared to TOI's ROE of +21.04%. Regarding short-term risk, NAKAW is more volatile compared to TOI. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check TOI's competition here
NAKAW vs CSU Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, NAKAW is priced at $15.30, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas CSU's P/E ratio is 0.67. In terms of profitability, NAKAW's ROE is -0.74%, compared to CSU's ROE of -3.25%. Regarding short-term risk, NAKAW is more volatile compared to CSU. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check CSU's competition here
NAKAW vs AGL Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, AGL has a market cap of 180.7M. Regarding current trading prices, NAKAW is priced at $15.30, while AGL trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas AGL's P/E ratio is -0.56. In terms of profitability, NAKAW's ROE is -0.74%, compared to AGL's ROE of -0.73%. Regarding short-term risk, NAKAW is more volatile compared to AGL. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check AGL's competition here
NAKAW vs JYNT Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, JYNT has a market cap of 142.2M. Regarding current trading prices, NAKAW is priced at $15.30, while JYNT trades at $9.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas JYNT's P/E ratio is -936.00. In terms of profitability, NAKAW's ROE is -0.74%, compared to JYNT's ROE of -0.04%. Regarding short-term risk, NAKAW is more volatile compared to JYNT. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check JYNT's competition here
NAKAW vs AIRS Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, AIRS has a market cap of 117.4M. Regarding current trading prices, NAKAW is priced at $15.30, while AIRS trades at $1.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas AIRS's P/E ratio is -6.27. In terms of profitability, NAKAW's ROE is -0.74%, compared to AIRS's ROE of -0.22%. Regarding short-term risk, NAKAW is more volatile compared to AIRS. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check AIRS's competition here
NAKAW vs BTMD Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, BTMD has a market cap of 100.5M. Regarding current trading prices, NAKAW is priced at $15.30, while BTMD trades at $2.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas BTMD's P/E ratio is 2.66. In terms of profitability, NAKAW's ROE is -0.74%, compared to BTMD's ROE of -0.33%. Regarding short-term risk, NAKAW is more volatile compared to BTMD. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check BTMD's competition here
NAKAW vs FVE Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, NAKAW is priced at $15.30, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas FVE's P/E ratio is -5.64. In terms of profitability, NAKAW's ROE is -0.74%, compared to FVE's ROE of -0.15%. Regarding short-term risk, NAKAW is more volatile compared to FVE. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check FVE's competition here
NAKAW vs KDLYW Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, NAKAW is priced at $15.30, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas KDLYW's P/E ratio is N/A. In terms of profitability, NAKAW's ROE is -0.74%, compared to KDLYW's ROE of -0.74%. Regarding short-term risk, NAKAW is more volatile compared to KDLYW. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check KDLYW's competition here
NAKAW vs DCGO Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, DCGO has a market cap of 77.5M. Regarding current trading prices, NAKAW is priced at $15.30, while DCGO trades at $0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas DCGO's P/E ratio is -1.49. In terms of profitability, NAKAW's ROE is -0.74%, compared to DCGO's ROE of -0.17%. Regarding short-term risk, NAKAW is more volatile compared to DCGO. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check DCGO's competition here
NAKAW vs ALR Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, NAKAW is priced at $15.30, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas ALR's P/E ratio is -1.11. In terms of profitability, NAKAW's ROE is -0.74%, compared to ALR's ROE of -0.15%. Regarding short-term risk, NAKAW is more volatile compared to ALR. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check ALR's competition here
NAKAW vs IMAC Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, NAKAW is priced at $15.30, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas IMAC's P/E ratio is -2.27. In terms of profitability, NAKAW's ROE is -0.74%, compared to IMAC's ROE of +1183.61%. Regarding short-term risk, NAKAW is more volatile compared to IMAC. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check IMAC's competition here
NAKAW vs CCEL Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, CCEL has a market cap of 27.3M. Regarding current trading prices, NAKAW is priced at $15.30, while CCEL trades at $3.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas CCEL's P/E ratio is -56.50. In terms of profitability, NAKAW's ROE is -0.74%, compared to CCEL's ROE of -0.03%. Regarding short-term risk, NAKAW is more volatile compared to CCEL. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check CCEL's competition here
NAKAW vs AIH Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, NAKAW is priced at $15.30, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas AIH's P/E ratio is -2.78. In terms of profitability, NAKAW's ROE is -0.74%, compared to AIH's ROE of +1.16%. Regarding short-term risk, NAKAW is more volatile compared to AIH. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check AIH's competition here
NAKAW vs AMS Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, AMS has a market cap of 14.3M. Regarding current trading prices, NAKAW is priced at $15.30, while AMS trades at $2.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas AMS's P/E ratio is -6.21. In terms of profitability, NAKAW's ROE is -0.74%, compared to AMS's ROE of -0.09%. Regarding short-term risk, NAKAW is more volatile compared to AMS. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check AMS's competition here
NAKAW vs CANO Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, NAKAW is priced at $15.30, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas CANO's P/E ratio is -0.01. In terms of profitability, NAKAW's ROE is -0.74%, compared to CANO's ROE of -1.49%. Regarding short-term risk, NAKAW is more volatile compared to CANO. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check CANO's competition here
NAKAW vs FTRP Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, NAKAW is priced at $15.30, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas FTRP's P/E ratio is -1.22. In terms of profitability, NAKAW's ROE is -0.74%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, NAKAW is more volatile compared to FTRP. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check FTRP's competition here
NAKAW vs TOIIW Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, TOIIW has a market cap of 8.9M. Regarding current trading prices, NAKAW is priced at $15.30, while TOIIW trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas TOIIW's P/E ratio is N/A. In terms of profitability, NAKAW's ROE is -0.74%, compared to TOIIW's ROE of +21.04%. Regarding short-term risk, NAKAW is more volatile compared to TOIIW. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check TOIIW's competition here
NAKAW vs PIII Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, PIII has a market cap of 7M. Regarding current trading prices, NAKAW is priced at $15.30, while PIII trades at $2.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas PIII's P/E ratio is -0.04. In terms of profitability, NAKAW's ROE is -0.74%, compared to PIII's ROE of -3.18%. Regarding short-term risk, NAKAW is more volatile compared to PIII. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check PIII's competition here
NAKAW vs MODV Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, NAKAW is priced at $15.30, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas MODV's P/E ratio is -0.03. In terms of profitability, NAKAW's ROE is -0.74%, compared to MODV's ROE of +1.84%. Regarding short-term risk, NAKAW is more volatile compared to MODV. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check MODV's competition here
NAKAW vs GBNH Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, NAKAW is priced at $15.30, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas GBNH's P/E ratio is -0.06. In terms of profitability, NAKAW's ROE is -0.74%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, NAKAW is more volatile compared to GBNH. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check GBNH's competition here
NAKAW vs TALKW Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, TALKW has a market cap of 5.3M. Regarding current trading prices, NAKAW is priced at $15.30, while TALKW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas TALKW's P/E ratio is N/A. In terms of profitability, NAKAW's ROE is -0.74%, compared to TALKW's ROE of -0.05%. Regarding short-term risk, NAKAW is more volatile compared to TALKW. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check TALKW's competition here
NAKAW vs RHE-PA Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, NAKAW is priced at $15.30, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, NAKAW's ROE is -0.74%, compared to RHE-PA's ROE of -0.04%. Regarding short-term risk, NAKAW is more volatile compared to RHE-PA. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check RHE-PA's competition here
NAKAW vs RHE Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, NAKAW is priced at $15.30, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas RHE's P/E ratio is -1.79. In terms of profitability, NAKAW's ROE is -0.74%, compared to RHE's ROE of +0.06%. Regarding short-term risk, NAKAW is more volatile compared to RHE. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check RHE's competition here
NAKAW vs ATIP Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, ATIP has a market cap of 3M. Regarding current trading prices, NAKAW is priced at $15.30, while ATIP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas ATIP's P/E ratio is -0.03. In terms of profitability, NAKAW's ROE is -0.74%, compared to ATIP's ROE of +0.23%. Regarding short-term risk, NAKAW is more volatile compared to ATIP. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check ATIP's competition here
NAKAW vs IMACW Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, NAKAW is priced at $15.30, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas IMACW's P/E ratio is N/A. In terms of profitability, NAKAW's ROE is -0.74%, compared to IMACW's ROE of +1.05%. Regarding short-term risk, NAKAW is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for NAKAW.Check IMACW's competition here
NAKAW vs SYRA Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, SYRA has a market cap of 1M. Regarding current trading prices, NAKAW is priced at $15.30, while SYRA trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas SYRA's P/E ratio is -1.13. In terms of profitability, NAKAW's ROE is -0.74%, compared to SYRA's ROE of -0.51%. Regarding short-term risk, NAKAW is more volatile compared to SYRA. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check SYRA's competition here
NAKAW vs MNDR Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, MNDR has a market cap of 903.5K. Regarding current trading prices, NAKAW is priced at $15.30, while MNDR trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas MNDR's P/E ratio is -0.05. In terms of profitability, NAKAW's ROE is -0.74%, compared to MNDR's ROE of -1.29%. Regarding short-term risk, NAKAW is more volatile compared to MNDR. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check MNDR's competition here
NAKAW vs CCM Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, CCM has a market cap of 473.2K. Regarding current trading prices, NAKAW is priced at $15.30, while CCM trades at $3.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas CCM's P/E ratio is -0.60. In terms of profitability, NAKAW's ROE is -0.74%, compared to CCM's ROE of +0.07%. Regarding short-term risk, NAKAW is more volatile compared to CCM. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check CCM's competition here
NAKAW vs BACK Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, BACK has a market cap of 212K. Regarding current trading prices, NAKAW is priced at $15.30, while BACK trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas BACK's P/E ratio is -0.02. In terms of profitability, NAKAW's ROE is -0.74%, compared to BACK's ROE of +1.05%. Regarding short-term risk, NAKAW is more volatile compared to BACK. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check BACK's competition here
NAKAW vs NVOS Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, NVOS has a market cap of 67.1K. Regarding current trading prices, NAKAW is priced at $15.30, while NVOS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas NVOS's P/E ratio is N/A. In terms of profitability, NAKAW's ROE is -0.74%, compared to NVOS's ROE of -0.81%. Regarding short-term risk, NAKAW is more volatile compared to NVOS. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check NVOS's competition here
NAKAW vs NIVFW Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, NIVFW has a market cap of 35.3K. Regarding current trading prices, NAKAW is priced at $15.30, while NIVFW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas NIVFW's P/E ratio is N/A. In terms of profitability, NAKAW's ROE is -0.74%, compared to NIVFW's ROE of +1.17%. Regarding short-term risk, NAKAW is more volatile compared to NIVFW. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check NIVFW's competition here
NAKAW vs PIIIW Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, PIIIW has a market cap of 18.9K. Regarding current trading prices, NAKAW is priced at $15.30, while PIIIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas PIIIW's P/E ratio is N/A. In terms of profitability, NAKAW's ROE is -0.74%, compared to PIIIW's ROE of -3.18%. Regarding short-term risk, NAKAW is more volatile compared to PIIIW. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check PIIIW's competition here
NAKAW vs IONM Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, IONM has a market cap of 1.6K. Regarding current trading prices, NAKAW is priced at $15.30, while IONM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas IONM's P/E ratio is N/A. In terms of profitability, NAKAW's ROE is -0.74%, compared to IONM's ROE of +5.28%. Regarding short-term risk, NAKAW is more volatile compared to IONM. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check IONM's competition here
NAKAW vs TVTY Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, TVTY has a market cap of 0. Regarding current trading prices, NAKAW is priced at $15.30, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas TVTY's P/E ratio is 19.06. In terms of profitability, NAKAW's ROE is -0.74%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, NAKAW is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check TVTY's competition here
NAKAW vs DCGOW Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, NAKAW is priced at $15.30, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas DCGOW's P/E ratio is N/A. In terms of profitability, NAKAW's ROE is -0.74%, compared to DCGOW's ROE of -0.17%. Regarding short-term risk, NAKAW is more volatile compared to DCGOW. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check DCGOW's competition here
NAKAW vs TLMDW Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, NAKAW is priced at $15.30, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas TLMDW's P/E ratio is N/A. In terms of profitability, NAKAW's ROE is -0.74%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, NAKAW is more volatile compared to TLMDW. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check TLMDW's competition here
NAKAW vs TLMD Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, TLMD has a market cap of 0. Regarding current trading prices, NAKAW is priced at $15.30, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas TLMD's P/E ratio is -1.60. In terms of profitability, NAKAW's ROE is -0.74%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, NAKAW is more volatile compared to TLMD. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check TLMD's competition here
NAKAW vs SLHGP Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, NAKAW is priced at $15.30, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, NAKAW's ROE is -0.74%, compared to SLHGP's ROE of -0.71%. Regarding short-term risk, NAKAW is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check SLHGP's competition here
NAKAW vs NFH Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, NFH has a market cap of 0. Regarding current trading prices, NAKAW is priced at $15.30, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas NFH's P/E ratio is -19.75. In terms of profitability, NAKAW's ROE is -0.74%, compared to NFH's ROE of -0.06%. Regarding short-term risk, NAKAW is more volatile compared to NFH. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check NFH's competition here
NAKAW vs HNGR Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, HNGR has a market cap of 0. Regarding current trading prices, NAKAW is priced at $15.30, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas HNGR's P/E ratio is 19.71. In terms of profitability, NAKAW's ROE is -0.74%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, NAKAW is more volatile compared to HNGR. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check HNGR's competition here
NAKAW vs DVCR Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, DVCR has a market cap of 0. Regarding current trading prices, NAKAW is priced at $15.30, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas DVCR's P/E ratio is 28.34. In terms of profitability, NAKAW's ROE is -0.74%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, NAKAW is more volatile compared to DVCR. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check DVCR's competition here
NAKAW vs SLHG Comparison February 2026
NAKAW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NAKAW stands at 116.4M. In comparison, SLHG has a market cap of 0. Regarding current trading prices, NAKAW is priced at $15.30, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NAKAW currently has a P/E ratio of N/A, whereas SLHG's P/E ratio is -1.48. In terms of profitability, NAKAW's ROE is -0.74%, compared to SLHG's ROE of N/A. Regarding short-term risk, NAKAW is more volatile compared to SLHG. This indicates potentially higher risk in terms of short-term price fluctuations for NAKAW.Check SLHG's competition here